In conclusion, the KD enhanced the anti-tumor efficacy of Bev in a glioblastoma intracranial implantation mouse model, based on lowest levels of cellular proliferation markers (Ki67 and CCND1) in Beb + KD-tumors compared to the other groups. Here, MKI67 is linked to neoplasm.